Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
65 hedge funds and large institutions have $191M invested in Poseida Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 14 reducing their positions, and 15 closing their positions.
482% more call options, than puts
Call options by funds: $763K | Put options by funds: $131K
71% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 14
8% less funds holding
Funds holding: 71 → 65 (-6)
32% less capital invested
Capital invested by funds: $279M → $191M (-$88.4M)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.59M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$849K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$694K |
| 4 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
+$416K |
| 5 |
JP Morgan Chase
New York
|
+$355K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$12.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.45M |
| 3 |
Millennium Management
New York
|
-$1.17M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$861K |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$857K |
PSTX Hedge Fund Activity: Q3 2021 in Review
65 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q3 2021, worth a combined $191M — down 32% from $279M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PSTX and 9 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 24 added.
The largest buyer was Vanguard Group, adding an estimated $1.59M. The largest seller was Boxer Capital, exiting entirely with an estimated $12.5M sold.
- 65 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q3 2021, down from 71 in Q2 2021.
- Funds reported $191M of Poseida Therapeutics, Inc. Common Stock stock for Q3 2021, down 32% quarter-over-quarter.
- 9 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q3 2021 and 15 closed out, a net change of -6 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q3 2021 was Vanguard Group, an estimated $1.59M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q3 2021 was Boxer Capital, an estimated $12.5M sold.
Based on aggregated 13F filings for Q3 2021.